Guardant Health Stock Forecast, Price & News

10 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Guardant Health in the last year. There are currently 10 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" Guardant Health stock.
View analyst ratings for Guardant Health or view top-rated stocks.

10 analysts have issued twelve-month price targets for Guardant Health's stock. Their GH stock forecasts range from $65.00 to $165.00. On average, they anticipate Guardant Health's share price to reach $126.90 in the next year. This suggests a possible upside of 200.3% from the stock's current price.
View analysts' price targets for Guardant Health or view top-rated stocks among Wall Street analysts.

Guardant Health's stock was trading at $100.02 at the beginning of the year. Since then, GH stock has decreased by 57.7% and is now trading at $42.26.
View the best growth stocks for 2022 here.

Guardant Health is scheduled to release its next quarterly earnings announcement on Thursday, August 4th 2022.
View our earnings forecast for Guardant Health.

Guardant Health, Inc. (NASDAQ:GH) released its earnings results on Thursday, May, 5th. The company reported ($1.21) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($1.23) by $0.02. The business earned $96.10 million during the quarter, compared to the consensus estimate of $95.71 million. Guardant Health had a negative trailing twelve-month return on equity of 62.68% and a negative net margin of 107.20%. Guardant Health's quarterly revenue was up 22.2% compared to the same quarter last year. During the same period last year, the business earned ($1.06) earnings per share.
View Guardant Health's earnings history.

Guardant Health issued an update on its FY 2022 earnings guidance on Monday, May, 30th. The company provided EPS guidance of for the period. The company issued revenue guidance of $460.00 million-$470.00 million, compared to the consensus revenue estimate of $465.93 million.

52 employees have rated Guardant Health CEO Helmy Eltoukhy on Glassdoor.com. Helmy Eltoukhy has an approval rating of 95% among Guardant Health's employees. This puts Helmy Eltoukhy in the top 30% of approval ratings compared to other CEOs of publicly-traded companies.

Some companies that are related to Guardant Health include Quest Diagnostics (DGX), Exact Sciences (EXAS), Natera (NTRA), Elekta AB (publ) (EKTAY), Fulgent Genetics (FLGT), Veracyte (VCYT), CareDx (CDNA), RadNet (RDNT), Castle Biosciences (CSTL), Invitae (NVTA), Viridian Therapeutics (VRDN), Burning Rock Biotech (BNR), Personalis (PSNL), DermTech (DMTK) and Renalytix (RNLX).
View all of GH's competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Guardant Health investors own include NVIDIA (NVDA), Trade Desk (TTD), Square (SQ), Alibaba Group (BABA), PayPal (PYPL), Shopify (SHOP), Okta (OKTA), Alteryx (AYX), Roku (ROKU) and Twilio (TWLO).

(GH) raised $200 million in an initial public offering (IPO) on Thursday, October 4th 2018. The company issued 12,500,000 shares at a price of $15.00-$17.00 per share. J.P. Morgan and BofA Merrill Lynch served as the underwriters for the IPO and Cowen, Leerink Partners and William Blair were co-managers.

Guardant Health trades on the NASDAQ under the ticker symbol "GH."

Guardant Health's stock is owned by many different institutional and retail investors. Top institutional shareholders include Vanguard Group Inc. (8.59%), Capital International Investors (4.99%), Capital Research Global Investors (3.93%), Clearbridge Investments LLC (3.29%), Goldman Sachs Group Inc. (1.66%) and Massachusetts Financial Services Co. MA (1.18%). Company insiders that own Guardant Health stock include Amirali Talasaz, Bluebird (Cayman) Ltd Svf, Derek A Bertocci, Helmy Eltoukhy, Ian T Clark, Michael J Wiley, Richard B Lanman, Samir Kaul, Stanley J Meresman, Stanley J Meresman, Timothy P Eckersley and Vision Fund (Aiv M1) Softbank.
View institutional ownership trends for Guardant Health.

GH stock was sold by a variety of institutional investors in the last quarter, including Nicholas Investment Partners LP, Capital Research Global Investors, Russell Investments Group Ltd., Zurcher Kantonalbank Zurich Cantonalbank , Chevy Chase Trust Holdings Inc., Group One Trading L.P., RTW Investments LP, and LA Financiere DE L Echiquier. Company insiders that have sold Guardant Health company stock in the last two years include Amirali Talasaz, Bluebird (Cayman) Ltd Svf, Derek A Bertocci, Helmy Eltoukhy, Ian T Clark, Samir Kaul, and Stanley J Meresman.
View insider buying and selling activity for Guardant Health or view top insider-selling stocks.

GH stock was acquired by a variety of institutional investors in the last quarter, including Capital International Investors, Steadfast Capital Management LP, RA Capital Management L.P., Alyeska Investment Group L.P., Ensign Peak Advisors Inc, Blue Water Life Science Advisors LP, Clearbridge Investments LLC, and Artemis Investment Management LLP.
View insider buying and selling activity for Guardant Health or or view top insider-buying stocks.

Shares of GH can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of GH stock can currently be purchased for approximately $42.26.

Guardant Health (NASDAQ:GH) has a market capitalization of $4.31 billion and generates $373.65 million in revenue each year. The company earns $-405.67 million in net income (profit) each year or ($4.12) on an earnings per share basis.

Guardant Health employs 1,373 workers across the globe.

Guardant Health's mailing address is 505 PENOBSCOT DR., REDWOOD CITY CA, 94063. The official website for Guardant Health is www.guardanthealth.com. The company can be reached via phone at (855) 698-8887, via email at [email protected], or via fax at 888-974-4258.